Sponsored Links
| Millennium Initiates First Clinical Trial With The First Oral Proteasome Inhibitor |
 |
 |
 |
| Medical News - Lymphoma and Leukemia | |||
|
Millennium: The Takeda Oncology Company announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March... Read more: Lymphoma / Leukemia / Myeloma News From Medical News Today
|